RENE Share Price Performance
UK£0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
RENE Community Narratives
There are no narratives available yet.
Recent RENE News & Updates
No updates
ReNeuron Group plc Key Details
Last Reported Earnings
Sep 30, 2023
Next Reporting Earnings
May 30, 2024
- Earnings per share (EPS)
- -0.089
- Gross Margin
- -1,367.47%
- Net Profit Margin
- -2,037.35%
- Debt/Equity Ratio
- 0%
ReNeuron Group plc Competitors
About RENE
- Founded
- 1997
- Employees
- 26
- CEO
- WebsiteView website
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
U.K. Market Performance
- 7 Days: -2.6%
- 3 Months: 18.0%
- 1 Year: 16.0%
- Year to Date: 12.3%
Over the last 7 days, the market has dropped 2.6%, driven by pullbacks in the Energy and Materials sectors of 4.0% and 4.2%, respectively. In the last year, the market is actually up 16%. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading